These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34434479)

  • 1. Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Nishimatsu K; Minami S; Ihara S; Yasuoka H
    J Med Cases; 2021 Aug; 12(8):310-314. PubMed ID: 34434479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
    Masuda K; Tokito T; Azuma K; Yanagida E; Nakamura M; Naito Y; Matsuo N; Ishii H; Yamada K; Akiba J; Hoshino T
    Thorac Cancer; 2018 Jun; 9(6):754-757. PubMed ID: 29675860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report.
    Taniguchi Y; Horiuchi H; Morikawa T; Usui K
    Case Rep Oncol; 2018; 11(2):323-329. PubMed ID: 29928211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.
    Sonoda T; Nishikawa S; Sakakibara R; Saiki M; Ariyasu R; Koyama J; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ninomiya H; Ishikawa Y; Nishio M
    Respir Med Case Rep; 2018; 24():19-21. PubMed ID: 29977749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
    Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
    Lee K; Kim Y; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Choi YL; Sun JM
    Lung Cancer; 2019 Apr; 130():87-92. PubMed ID: 30885357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report.
    Lee S; Joo J; Kwak M; Sohn K; Chon S
    Onco Targets Ther; 2018; 11():3943-3947. PubMed ID: 30022837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Riely GJ
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S146-9. PubMed ID: 18520300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Observational Study of Acquired
    Wu SG; Chiang CL; Liu CY; Wang CC; Su PL; Hsia TC; Shih JY; Chang GC
    Front Oncol; 2020; 10():1481. PubMed ID: 33014788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report.
    Wang YF; Xiang X; Pei X; Li S; Tang C; Wang L; Ke ZF
    Oncol Lett; 2014 Sep; 8(3):1039-1042. PubMed ID: 25120654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
    De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
    J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
    Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.